Reduce the incidence and overall severity of E. coli scours
Kavault is a first-in-class antimicrobial proven to reduce the incidence and overall severity of diarrhea in the presence of pathogenic Escherichia coli in groups of weaned pigs, during the phase when pigs are most at risk.
E.coli prevalence and impact
Pathogenic E. coli is costly and prevalent in the swine industry. One of the most important causes of post-weaning diarrhea (PWD) in pigs, it ranks among the most common diseases overall in global swine production.1 A major source of frustration and worry, E. coli costs producers in prevention, diagnosis, treatment, mortality, and reduced performance.
At the post-weaning stage, pigs are at risk of E. coli exposure from common conditions like transport, relocation, commingling, loss of maternal antibodies, and change to a solid diet. Clinical signs of E. coli typically appear 5-15 days after weaning and can last for 21 days or more. During this time, the disease can significantly affect herd health and performance.2
Avilamycin, the active ingredient in Kavault, is a first-in-class orthosomycin antibiotic. Developed exclusively for use in food animals, it has never been used in humans and is defined as non-medically important by FDA Guidance 152.3 Avilamycin's animal use only profile aligns with responsible antibiotic use. Avilamycin also has established maximum residue limits with CODEX and the EU, and is only available with a veterinary feed directive (VFD).